Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines (2021)

First Author: Monin-Aldama L
Attributed to:  Phase 1 COVID-19 Immunity - National Core Study funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.03.17.21253131

Publication URI: http://dx.doi.org/10.1101/2021.03.17.21253131

Type: Preprint